Aims: We evaluated the efficacy and safety of erlotinib, and patient characteristics affecting
progression-free survival (PFS), by analyzing data from two Phase II studies of first-line …

Background The clinical benefit of erlotinib in treating epidermal growth factor receptor
(EGFR) wildtype non-small cell lung cancer (NSCLC) has been questioned. We examined …

Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …

Abstract Tarceva Lung cancer Survival Treatment (TRUST) was an open-label, phase IV
study of advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …

Purpose There is as yet no optimal treatment regimen for patients with epidermal growth
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …

Erlotinib hydrochloride (Tarceva®) is a member of a class of small molecule inhibitors that
targets the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), with anti …

Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …

Purpose Histone deacetylase inhibitors (HDACis) have been shown to overcome resistance
to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) linked to …

Background Several clinical trials showed that erlotinib was effective after the failure of
gefitinib in advanced non-small cell lung cancer (NSCLC). The aim of this study was to …

The first-line treatment of advanced non-small-cell lung cancer (NSCLC) generally consists
of a maximum of six cycles of platinum-based doublet chemotherapy followed by …